1. Home
  2. LU vs OGN Comparison

LU vs OGN Comparison

Compare LU & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lufax Holding Ltd each representing two (2)

LU

Lufax Holding Ltd each representing two (2)

HOLD

Current Price

$1.42

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Organon & Co.

OGN

Organon & Co.

HOLD

Current Price

$13.52

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LU
OGN
Founded
2005
1923
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
LU
OGN
Price
$1.42
$13.52
Analyst Decision
Hold
Hold
Analyst Count
1
5
Target Price
$2.00
$11.40
AVG Volume (30 Days)
1.5M
2.3M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
0.60%
EPS Growth
N/A
N/A
EPS
N/A
0.55
Revenue
N/A
$6,216,000,000.00
Revenue This Year
N/A
$0.45
Revenue Next Year
$22.52
$1.67
P/E Ratio
N/A
$24.64
Revenue Growth
N/A
N/A
52 Week Low
$1.20
$5.69
52 Week High
$4.57
$13.60

Technical Indicators

Market Signals
Indicator
LU
OGN
Relative Strength Index (RSI) 48.55 68.64
Support Level $1.29 $10.05
Resistance Level $2.77 N/A
Average True Range (ATR) 0.07 0.06
MACD 0.03 -0.05
Stochastic Oscillator 89.80 59.52

Price Performance

Historical Comparison
LU
OGN

About LU Lufax Holding Ltd each representing two (2)

Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.

About OGN Organon & Co.

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

Share on Social Networks: